Linzagolix (choline)

Linzagolix (choline)

• CAS Number: 1321816-57-2
• UNSPSC Description: Linzagolix choline (KLH-2109 choline) is a non-peptide gonadotropin-releasing hormone (GnRH) antagonist with oral activity. Linzagolix choline inhibits the release of endogenous gonadotropins such as luteinizing hormone LH and follicle-stimulating hormone FSH by binding to the GnRH receptor within the pituitary gland. This inhibition results in a reduction in the production of sex hormones such as estrogen and progesterone, which in turn affects the course of sex hormone-dependent diseases. Linzagolix choline can be used in the study of sex hormone-dependent diseases such as endometriosis and uterine fibroids[1].
• Target Antigen: GnRH Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein
• Applications: COVID-19-immunoregulation
• Field of Research: Cancer; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/linzagolix-choline.html
• Smiles: OCC[N+](C)(C)C.O=C([O-])C1=C(C(NC2=O)=CS1)C(N2C3=CC(OCC4=C(C=CC(F)=C4F)OC)=C(C=C3F)OC)=O
• Molecular Weight: 611.59
• References & Citations: [1]Kobayashi K, et al. Non-clinical studies indicating lack of interactions between iron/calcium ions and linzagolix, an orally available GnRH antagonist[J]. Xenobiotica, 2022, 52(5): 488-497.
• Shipping Conditions: Room temperature
• Clinical Information: Launched